Antitrust Antitrust

Forest Laboratories urges US judge to dismiss Bystolic pay-for-delay lawsuit

By Michael Acton
  • 14 Dec 2021 17:57
  • 14 Dec 2021 18:30
Lawyers for Forest Laboratories — now part of Allergan — urged a US judge in New York today to dismiss a lawsuit accusing the company of striking illegal pay-for-delay patent settlements with other drugmakers to delay the market entry of generic versions of beta blocker Bystolic.
During a lengthy hearing,

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Michael Acton

Senior Correspondent

Michael is a senior correspondent for MLex in San Francisco, where he moved in 2020 after working in our Brussels bureau. Before joining MLex, he reported on EU politics as the Financial Times’ Nico Colchester Fellow in Brussels. Michael has a degree in International Relations and Politics from the University of Cambridge, and a degree in History and French from University College London and Paris IV Sorbonne.

Discover MLex

Stay on top of global regulatory developments

Latest News